Maria has 30 years of experience in the life science and diagnostic industry and she has previously held senior management positions as CEO, business area manager and marketing manager at international diagnostic companies such as Pharmacia Diagnostics, Boehringer Mannheim, Roche Scandinavia, Phadia and Thermo Fisher. She has extensive experience of successfully introducing novel diagnostic products globally. Maria is currently CEO of Prolight Diagnostics.
Holdings: 9 750 B-shares, 25 000 warrants 2019/2023 (TO4)

Jesper received an MSc in Engineering Physics from the Swedish Royal Institute of Technology and a PhD from the Royal Institute of Technology and CERN. Jesper is CEO of Arcoma AB. He was formerly Vice President of Elekta’s Neuroscience division and General Manager, Mammography, at Philips Healthcare and the CEO of Sectra Mamea, AB, from 2004 until it was acquired by Philips in 2011. In these positions, he managed the microdose mammography business, taking it from a start-up to an international medical technology company. Jesper has also held management positions at Huber+Suhner and at Allgon.
Holdings: 41 085 A-shares, 38 200 B-shares, 25 000 warrants 2019/2023 (TO4)

Marie-Louise, MD, Ph.D from Uppsala University. Marie-Louise is Chief Medical Officer at Sensei Biotherapeutics in Boston, USA. She was formerly Global Clinical Program Leader at Novartis Institute for Biomedical Research (NIBR), she held a position within Translational Clinical Oncology (TCO) and held global responsibility for developement of targeted treatments: CDK4/6, BCL-2, and immunotherapy (CSF-1, PD-1 och CD73) and as Vice President (VP) Clinical Development at Merus and Infinity Pharmaceuticals, Cambridge, USA.
Holdings: None